咳嗽和血管紧张素转换酶的抑制作用

• 作 者: 顾明君
• 出 处: 国外医药.合成药.生化药.制剂分册
• 发表日期: 1989年02期
• 关键词: 抑制作用 支气管反应性 收缩性 气道阻塞 前列腺素 间接作用 咳嗽病 缓激肽 酶抑制剂 张索

已报道咳嗽至少是4种血管紧张素转换酶抑制剂的副作用,至少250例病人中,与血管紧张素转换酶抑制剂有关的咳嗽发生率在0～3％,但在高血压病人中发生率较高。这种咳嗽在妇女(占报告的病例约2/3)和不吸烟者中较常见。气道阻塞、心力衰竭及治疗效果似不影响这种咳嗽。咳嗽病人与不咳嗽病人相比,支气管反应性增加或气道收缩性增加。血管紧张素转换酶抑制剂引起咳嗽的机理还不清楚。血管紧张素转换酶抑制剂通过缓激肽对前列腺素的生成有间接作用。前列

Cough has been reported to be a side effect of at least 4 angiotensin-converting enzyme inhibitors, with a prevalence of cough associated with angiotensin-converting enzyme inhibitors of at least 250 patients in 0-3%, but in hypertensive patients Higher. This cough is more common among women (about two-thirds of the reported cases) and non-smokers. Airway obstruction, heart failure and treatment effects do not seem to affect the cough. Patients with cough have increased bronchial reactivity or increased airway contractility compared with non-cough patients. The mechanism by which angiotensin-converting enzyme inhibitors cause coughing is unclear. Angiotensin-converting enzyme inhibitors have an indirect effect on prostaglandin production by bradykinin. Forefront